Johnson & Johnson (JNJ): At ESMO, Impressive First-in-Class Prostate Cancer Data Draws Attention and OrigAMI-4 Clears the Bar

At the ongoing ESMO 2026 conference, JNJ reported impressive though early Phase 1 results in advanced metastatic castration-resistant prostate cancer for JNJ-6143, acquired via Halda, part of the novel RIPTAC (Regulated Induced Proximity Targeting Chimera) platform. Investor conversations suggest this was an unexpected upside surprise that had flown under the radar and was cited among the key highlights of the conference. JNJ-6143 showed a high rate of durable radiographic responses, strong PSA50/PSA90 declines and a very tolerable safety profile in a heavily pretreated, late-line population. The discussant framed the data as setting the stage for larger trials in earlier settings and as a combination partner for established drugs. Separately, Phase 1b/2 OrigAMI-4 (Cohort 5) data for first-line subcutaneous Rybrevant plus Keytruda and chemotherapy in non-HPV head and neck squamous cell carcinoma also cleared the bar, with a high confirmed overall response rate, tumor shrinkage in all e